Jm. Planquois et al., SALBUTAMOL POTENTIATES THE RELAXANT EFFECTS OF SELECTIVE PHOSPHODIESTERASE INHIBITORS ON GUINEA-PIG ISOLATED TRACHEA, Fundamental and clinical pharmacology, 10(4), 1996, pp. 356-367
The ability of low concentrations of salbutamol to potentiate the rela
xant effects of the phosphodiesterase (PDE) inhibitors, rolipram, Po 2
0-1724 (PDE type IV inhibitor), siguazodan and milrinone (PDE type III
inhibitor) was studied on guinea pig isolated trachea. These PDE inhi
bitors were strong relaxants of guinea pig trachealis under basal tone
, but had only a weak activity on tissues precontracted with histamine
(10(-5) M). In both cases, PDE type IV inhibitors showed a relaxant e
ffect composed of two phases. The first phase represented 20 and 40% a
nd the second, 90 and 140%, respectively, of relaxation of basal tone
and histamine-induced tone. A second characteristic of PDE type IV inh
ibitors was the very fast and partially reversible relaxation observed
at concentrations greater than 3 x 10(-8) M (for histamine-induced to
ne) at the first addition of inhibitor, followed by a residual relaxan
t activity. The latter relaxant effect was stable at concentrations of
3 x 10(-8)-10(-5) M and was equivalent to a 20% relaxation (for hista
mine-induced tone). In the presence of low concentrations (10(-9) and
10(-8) M) of salbutamol, there was a significant concentration-depende
nt potentiation of the effects of PDE inhibitors on trachea precontrac
ted with histamine. Salbutamol, at a concentration of 10(-9) M, potent
iated the effects of PDE inhibitors between 1.4- and 3.6-fold. In the
presence of salbutamol 10(-8) M, the potentiation was more marked for
siguazodan (37.9-fold), milrinone (11.0-fold) and Po 20-1724 (14.5-fol
d) than for rolipram (4.3-fold). These results suggest that low concen
trations of salbutamol can potentiate the relaxant effects of both PDE
type III and PDE type IV inhibitors. Thus, PDE type IV inhibitors, wh
ich have antiinflammatory properties, could also provide adequate bron
chodilation when used in combination with lower than usual doses of be
ta(2)-agonists.